Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 05, 2007. The report serves to disclose details regarding the appointment of a new Non-Executive Director, Dr. Stephanie Burns, in compliance with the Financial Services Authority's Listing Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance disclosure rather than a financial results report.
Material Changes
The primary material change disclosed is the appointment of Dr. Stephanie Burns to the Board of Directors. The filing notes that Dr. Burns has not served as a director of a publicly quoted company in the past five years.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses the disclosure requirements for the new director's shareholdings and background.
Important Facts for Investors
- Dr. Stephanie Burns has been appointed as a Non-Executive Director.
- Dr. Burns holds interests in 44 Ordinary Shares and 95 Ordinary Share ADRs of GlaxoSmithKline plc, acquired prior to her appointment.
- Dr. Burns has no additional details to disclose under paragraphs 9.6.13 R (2) to (6) of the FSA Listing Rules.
- The report was signed by Victoria Whyte, Authorised Signatory, on March 05, 2007.